Key result
Verapamil plus 4'epidoxorubicin induced partial remissions in 3 of 13 patients with anthracycline-refractory cancer.
Why the study?
Does verapamil plus 4'epidoxorubicin induce objective responses in anthracycline-refractory cancer patients?
Does verapamil plus 4'epidoxorubicin induce objective responses in anthracycline-refractory cancer patients?
Verapamil added to 4'epidoxorubicin can induce objective responses in some patients with anthracycline-refractory cancer.
Answers are grounded in this paper and cite their sources.
May support chemosensitization trials in refractory cancer; leaves open efficacy in randomized studies.
Four patients refractory to doxorubicin (DX) and 9 patients refractory to 4'epidoxorubicin (4'EpiDX) were treated with verapamil (VRP) (120 mg every 6 h for 3 days) plus 4'EpiDX (80 mg/m2 i.v. bolus, together with the 6th VRP administration). Three patients had partial remissions lasting 3, 3.5 and 7 months, respectively. Toxicity grading did not exceed usual levels. The study demonstrates that VRP, when added at conventional doses to 4'EpiDX, can induce objective responses in some patients refractory to anthracyclines.
No takes yet. Share an insight, caveat, or question.
Demicheli et al. (1989) studied Anthracycline-refractory cancer (n=13). Verapamil plus 4'epidoxorubicin was evaluated on Partial remission. Verapamil plus 4'epidoxorubicin induced partial remissions in 3 of 13 patients with anthracycline-refractory cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: